Last reviewed · How we verify

Pseudoephedrine Sustained Action

Washington University School of Medicine · FDA-approved active Small molecule Quality 2/100

Pseudoephedrine Sustained Action is a Small molecule drug developed by Washington University School of Medicine. It is currently FDA-approved. Also known as: Sudafed.

At a glance

Generic namePseudoephedrine Sustained Action
Also known asSudafed
SponsorWashington University School of Medicine
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Pseudoephedrine Sustained Action

What is Pseudoephedrine Sustained Action?

Pseudoephedrine Sustained Action is a Small molecule drug developed by Washington University School of Medicine.

Who makes Pseudoephedrine Sustained Action?

Pseudoephedrine Sustained Action is developed and marketed by Washington University School of Medicine (see full Washington University School of Medicine pipeline at /company/washington-university-school-of-medicine).

Is Pseudoephedrine Sustained Action also known as anything else?

Pseudoephedrine Sustained Action is also known as Sudafed.

What development phase is Pseudoephedrine Sustained Action in?

Pseudoephedrine Sustained Action is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing